Background: Polycystic ovary syndrome PCOs is a common hormonal disorder that affects women of childbearing age. Insulin resistance plays an important role in the pathogenesis of PCOs, especially menstrual disorders and infertility. In this study, we will try to find the importance of improving insulin resistance in achieving regular menstrual periods. Objective: Studying the correlation of menstrual disorders in polycystic ovary syndrome patients and insulin-resistant conditions to decide the best and the most effective treatment. Methods: This study included patients with polycystic ovary syndrome and insulin resistance who had visited obstetrics and gynecology clinic in Tishreen University Hospital, Lattakia. Insulin resistance was calculated for all patients at the first visit. In addition to clinical assessment with ultrasound examination. Results: This study included 65 women with insulin resistance and diagnosed with polycystic ovary syndrome. The age of the participants ranged between 22 - 40 years, with an average age of 28.3 ± 3.63 years. All of them suffered from menstrual disorders, bradymenorrhea accounted for the largest percentage of the sample, with more than 66% of cases. Conclusion: Our study found a significant role of reducing insulin resistance in improving ovulation and menstrual disorders in patients with Polycystic Ovary Syndrome (PCOs).
Cite this paper
Hayek, M. (2024). Study of Prevalence of Menstrual Disorders in Cases of Insulin Resistance in Patients with Polycystic Ovary Syndrome. Open Access Library Journal, 11, e2442. doi: http://dx.doi.org/10.4236/oalib.1112442.
Rosenfield, R.L. and Ehrmann, D.A. (2016) The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 37, 467-520. https://doi.org/10.1210/er.2015-1104
Kahsar-Miller, M.D., Nixon, C., Boots, L.R., Go, R.C. and Azziz, R. (2001) Prevalence of Polycystic Ovary Syn-drome (PCOS) in First-Degree Relatives of Patients with PCOS. Fertility and Ste-rility, 75, 53-58. https://doi.org/10.1016/s0015-0282(00)01662-9
Yildiz, B.O., Bolour, S., Woods, K., Moore, A. and Azziz, R. (2009) Visually Scoring Hirsutism. Human Reproduction Update, 16, 51-64. https://doi.org/10.1093/humupd/dmp024
American Academy of Pedi-atrics, Committee on Adolescence, et al. (2006) Menstruation in Girls and Ado-lescents: Using the Menstrual Cycle as a Vital Sign. Pediatrics, 118, 2245-2250. https://doi.org/10.1542/peds.2006-2481
van Hooff, M.H.A. (2004) Predictive Value of Menstrual Cycle Pattern, Body Mass Index, Hormone Levels and Polycystic Ovaries at Age 15 Years for Oligo-Amenorrhoea at Age 18 Years. Human Reproduction, 19, 383-392. https://doi.org/10.1093/humrep/deh079
Kirchengast, S. (2001) Body Composition Characteristics and Body Fat Distribution in Lean Women with Polycystic Ovary Syndrome. Human Reproduction, 16, 1255-1260. https://doi.org/10.1093/humrep/16.6.1255
Simpson, N.B. and Cunliffe, W.J. (2004) Disorders of the Sebaceous Glands. In: Burns, T., Breathnach, S., Cox, N. and Griffiths, C., Eds., Rook’s Text Book of Dermatology, 7th Edition, Blackwell Science, 1-75.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS). Human Reproduc-tion, 19, 41-47. https://doi.org/10.1093/humrep/deh098
Zawadski, J.K. and Dunaif, A. (1992) Diagnostic Criteria for Polycystic Ovary Syndrome: Towards a Rational Approach. In: Dunaif, A., Givens, J.R., Haseltine, F.P., Mer-riam, G.E., Eds., Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism), Blackwell Scientific Inc, 377.
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H.F., Futterweit, W., et al. (2009) The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: The Complete Task Force Report. Fertility and Sterility, 91, 456-488. https://doi.org/10.1016/j.fertnstert.2008.06.035
Jeffrey Chang, R. (2004) A Practical Approach to the Diagnosis of Polycystic Ovary Syndrome. American Journal of Obstetrics and Gynecology, 191, 713-717. https://doi.org/10.1016/j.ajog.2004.04.045
Kahn, S.E. (2003) The Rel-ative Contributions of Insulin Resistance and Beta-Cell Dysfunction to the Path-ophysiology of Type 2 Diabetes. Diabetologia, 46, 3-19. https://doi.org/10.1007/s00125-002-1009-0
Jalilian, N., Shahebrahimi, K., Bazgir, N. and Rezaei, M. (2016) Comparison Clinical and Metabolic Effects of Metformin and Pioglitazone in Polycystic Ovary Syndrome. Indian Journal of Endocrinology and Metabolism, 20, 805-809. https://doi.org/10.4103/2230-8210.192925
Ortega-Gonzalez, C., Luna, S., Hernandez, L., Crespo, G., Aguayo, P., Arteaga-Troncoso, G., et al. (2005) Re-sponses of Serum Androgen and Insulin Resistance to Metformin and Pioglita-zone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 90, 1360-1365. https://doi.org/10.1210/jc.2004-1965
Sohrevardi, S.M., Nosouhi, F., Khalilzade, S.H., Kafaie, P., Karimi-Zarchi, M., Halvaei, I., et al. (2016) Evaluat-ing the Effect of Insulin Sensitizers Metformin and Pioglitazone Alone and in Combination on Women with Polycystic Ovary Syndrome: An Rct. International Journal of Reproductive BioMedicine, 14, 743-754. https://doi.org/10.29252/ijrm.14.12.743
Devi, A.S. and Anuradha, J. (2017) Metfornim and Pioglitazone in Polycystic Ovarian Syndrome: A Compar-ative Study. International Archives of Integrated Medicine, 4, 39-44.
Chaudhry, I., Sadaf Un, N. and Shams Un, N. (2016) Comparison between Pioglitazone and Metformin in Terms of Efficacy in Patients with Poly-cystic Ovarian Syndrome. Pakistan Journal of Medical & Health Sciences, 10, 574-577.
